Shares of Vivus (NASDAQ:VVUS) are soaring today after news its drug QNEXA was found to lower weight and reduce blood pressure in trials.
When patients who had been treated with the top dose of QNEXA, results were they sustained a loss of weight of over 10 percent over a two-year period, while also experiencing a loss in blood pressure.
The drug also helped patients cut back on the need to use anti-hypertensive medications, while improving lipid levels compared to a dummy drug.
In 2010 the drug had been rejected by U.S. regulators because of cardiovascular safety concerns.
Vivus was trading at $6.80, gaining $0.49, or 7.77 percent, as of 2:07 PM EDT.
Monday, April 4, 2011
Vivus (VVUS) Rockin' It on QNEXA Results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment